Key result
An engineered inhibitor modified from honey bee venom toxin blocked Kir1 channels with high affinity (1 nM) and high selectivity (>250-fold) over other Kir subtypes.
The successful engineering of a highly specific and high-affinity inhibitor for Kir1 channels demonstrates the feasibility of creating subtype-specific K+ channel inhibitors for research and potential therapeutic use.
Engineered Kir1-selective inhibitor expands research tools; leaves open therapeutic translation pending further validation.
Inward-rectifier K(+) (Kir) channels play many important biological roles and are emerging as important therapeutic targets. Subtype-specific inhibitors would be useful tools for studying the channels' physiological functions. Unfortunately, available K(+) channel inhibitors generally lack the necessary specificity for their reliable use as pharmacological tools to dissect the various kinds of K(+) channel currents in situ. The highly conserved nature of the inhibitor targets accounts for the great difficulty in finding inhibitors specific for a given class of K(+) channels or, worse, individual subtypes within a class. Here, by modifying a toxin from the honey bee venom, we have successfully engineered an inhibitor that blocks Kir1 with high (1 nM) affinity and high (>250-fold) selectivity over many commonly studied Kir subtypes. This success not only yields a highly desirable tool but, perhaps more importantly, demonstrates the practical feasibility of engineering subtype-specific K(+) channel inhibitors.
No takes yet. Share an insight, caveat, or question.
Ramu et al. (2008) studied this question. Engineered inhibitor (modified honey bee venom toxin) was evaluated on Kir1 channel blockade affinity and selectivity. An engineered inhibitor modified from honey bee venom toxin blocked Kir1 channels with high affinity (1 nM) and high selectivity (>250-fold) over other Kir subtypes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: